Determinants of development and preservation of atrial fibrillation at thyrotoxicosis
Abstract
Atrial fibrillation is a frequent violation of a heart rhythm at thyrotoxicosis and it can determine serious complica tions (tromboembolia, stroke) and death. The study of factors increasing risk development of atrial fibrillation at thy rotoxicosis is investigating many years but the occurrence of new diagnostic methods and mathematic analysis allows to reveal new determinants of development of atrial fibrillation and its persistence after restoration of euthyreosis. In our research we’ve studied the Echocardiography parameters in 254 normotensive patients with a thyrotoxicosis Graves’ disease without any CVD and 110 patients with a subclinical thyrotoxicosis. We detected new factors of risk of atrial fibrillation: the duration of thyrotoxicosis and the left ventricular concentric hypertrophy. The contribution of different factors in development of atrial fibrillation is defined.
About the Authors
A Babenkokand. med. nauk, zaveduyushchaya NIL sosudistykh oslozhneniy sakharnogo diabeta instituta endokrinologii FTsSKE im. V.A. Almazova
E Grineva
doktor med. nauk, direktor instituta endokrinologii FTsSKE im. V.A. Almazova
V Solncev
kand. mat. nauk, starshiy nauchnyy sotrudnik NIL matematicheskogo modelirovaniya FTsSKE im. V.A. Almazova
References
1. Бабенко А.Ю. Тиреотоксическая кардиомиопатия: факторы риска и предикторы развития. Обзоры по клинической фар макологии и лекарственной терапии. 2011; 9 (3): 49–59.
2. Бабенко А.Ю., Гринева Е.Н., Солнцев В.Н., Цой У.А., Шлях то Е.В. Вклад различных факторов в характер поражения сердца при тиреотоксикозе. Мед. акад. журн. 2012. 10 (1): 6–12.
3. Боровиков В. Statistical искусство анализа данных на компью тере. Для профессионалов. СПб.: Питер, 2001. 656 с.
4. Ланг Т., Сесик М. Как описывать статистику в медицине. Ан нотированное руководство для авторов, редакторов и рецен зентов. М.: Практическая медицина, 2011. 480 с.
5. Орлов В.Н. Руководство по электрокардиографии. 6е изд., стереот. М.: Мед. информ. агентство, 2007. 525 с.
6. Шустов С.Б., Кицышин В.П. Особенности суточного распре деления нарушений ритма у больных с эндокринными кар диомиопатиями. Рус. мед. журн. http://www.rusmg.ru/php/ contents.php?id=9275
7. Auer J., Scheibner P., Mische T. et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am. Heart. J. 2001; 142: 838–842.
8. Bahn R.S. et al. Hyperthyroidism and other causes of thyrotoxico sis: management guidelines of the american thyroid association and american association of clinical endocrinologists. Endocrinol. Pract. 2011; 17: 456–520.
9. Cappola A.R., Fried L.P., Arnold A.M. et al. Thyroid status, cardio vascular risk, and mortality in older adults. JAMA 2006; 295 (9): 1033–1041.
10. Ching G.W., Franklyn J.A., Stallard T.J. et al. Cardiac hypertrophy as a result of longterm thyroxine therapy and thyrotoxicosis. Heart 1996; 75: 363–368.
11. De Simone G. Concentric or eccentric hypertrophy: how clinically relevant is the difference? Hypertension 2004; 43 (4): 714–715.
12. Donatelli M., Assennato P., Abbadi V. et al. Cardiac changes in sub clinical and overt hyperthyroid women: retrospective study. Int.
13. J. Cardiol. 2003; 90: 159–164.
14. Dorr M., Wolff B., Robinson D.M. et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J. Clin. Endocrinol. Metab. 2005; 90 (2): 673–677.
15. Dougherty M., Craige E. Apathetic hyperthyroidism presenting as tricuspid regurgitation. Chest. 1973; 63: 767–772.
16. Dunn M., Alexander J., de Silva R., Hildner F. Antithrombotic ther apy in atrial fibrillation. Chest. 1989; 95 (Suppl. 2): 118S–127S.
17. Ganau A., Devereux R.B., Roman M.J. et al. Patterns of left ven tricular hypertrophy and geometric remodeling in essential hyper tension. J. Am. Coll. Cardiol. 1992; 19: 1550–1558.
18. Flynn R.W.V., McDonald T.M., Jung R.T. et al. Mortality and vas cular outcomes in patients treated for thyroid dysfunction. J. Clin. Endocrinol. Metab. 2006; 91 (6): 2159–2164.
19. Franklyn J.A., Sheppard M.C., Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005; 294 (1): 71–80.
20. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a populationbased study. Arch. Intern. Med. 2004; 164: 1675–1678.
21. Iwasaki T., Naka M., Hiramatsu K. Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves' disease. Cardiology 1989; 76 (1): 10–17.
22. Lang R.M., Biering M., Devereux R.B. et al. Recommendations for chamber quantification: a report from the American of Society Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440–1463.
23. Marcisz C., Jonderko G., Wroblewski T. et al. Left ventricular mass in patients with hyperthyroidism. Med. Sci Monit. 2006; 12 (11): 481–486.
24. Marti V., Ballester M., Rigla M. et al. Myocardial damage does not occur in untreated hyperthyroidism unless associated with conges tive heart failure. Am. Heart J. 1997. 134 (6): 1133–1137.
25. Marvisi M., Zambrelli P., Brianty M. et al. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur. J. Intern. Med. 2006; 17 (4): 267–271.
26. Merce J., Ferras S., Oltra C. et al. Cardiovascular abnormalities in hyperthyroidism: A prospective Doppler echocardiographic study. Am. J. Med. 2005; 118: 126–131.
27. Metso S., Auvinen A., Salmi J. еt al. Increased longterm cardiovas cular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin. Endocrinol. 2007; 92: 2190–2196.
28. Mintz G., Pizzarello R., Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J. Clin. Endocrinol Metab. 1991; 73: 146–150.
29. Nakazawa H. et al. Is there a place for the late cardioversion of atri al fibrillation? A longterm followup study of patients with post thyrotoxic atrial fibrillation. Eur. Heart J. 2000; 21: 327–333.
30. Nakchbandi I.A., Wirth J.A., Inzucchi S.E. Pulmonary hyperten sion caused by Graves’ thyrotoxicosis normal pulmonary hemody namics restored by 131I treatment. Chest. 1999; 116: 1483–1485.
31. Osman F., Daykin J., Sheppard M. et al. Cardiac rhythm abnor malities in thyrotoxicosis — the explanation for excess vascular mortality. J. Endocrinol. 2000; 164: 321–322.
32. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibril lation. Stroke 1988; 19: 15–18.
33. Rubin L.J., Badesch D.B. Thyrotoxicosis as a risk factor for pul monary arterial hypertension. Ann. Intern. Med. 2006; 144 (3): 222–223.
34. Sandier G., Wilson G. The nature and prognosis of heart disease in thyrotoxicosis: a review of 150 patients treated with I131. QJM 1959; 28: 347–352.
35. Sheu J.J., Kang J.H., Lin H.C. et al. Hyperthyroidism and risk of ischemic stroke in young adults. Stroke 2010; 41 (5): 961–966.
36. Siu C.W., Yeung C.Y., Lau C.P. et al. Incidence, clinical character istics and outcome of congestive heart failure as the initial presen tation in patients with primary hyperthyroidism. Heart 2007; 93: 483–487.
37. Soh М.С., Croxson М. Fatal thyrotoxic cardiomyopathy in a young man. BMJ 2008; 337: 531.
38. Tenerz A., Forberg R., Jansson R. Is a more active attitude warrant ed in patients with subclinical thyrotoxicosis? J. Intern. Med. 1990; 228: 229–233.
39. Toft A., Boon N. Thyroid disease and the heart. Heart 2000; 84: 455–460.
Review
For citations:
, , Determinants of development and preservation of atrial fibrillation at thyrotoxicosis. Clinical and experimental thyroidology. 2013;9(1):29-37. (In Russ.)
Views:
1000
Email this article 
